Author details

Full Name

Bernhard Englinger

Affiliation

ORCID

Career Start Year

2015

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36759899	Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.	Acta Neuropathol Commun	2023
35640920	Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.	Neuro-Oncology	2023
36471067	The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.	Nat Genet	2022
36040810	VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.	JCI Insight	2022
35484633	Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.	Acta Neuropathol Commun	2022
34046693	Targeting fibroblast growth factor receptors to combat aggressive ependymoma.	Acta Neuropathol	2021
33894304	Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma.	J Control Release	2021
32663469	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma.	Cancer Cell	2020
32064608	Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.	International Journal of Cancer	2020
32493453	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients.	Acta neuropathologica communications	2020
32693052	Into Thin Air: Hypoxia Drives Metabolic and Epigenomic Deregulation of Lethal Pediatric Ependymoma.	Developmental Cell	2020
31002438	Subcellular Duplex DNA and G-Quadruplex Interaction Profiling of a Hexagonal Pt Metallacycle.	Angewandte Chemie - International Edition	2019
30489072	Metal Drugs and the Anticancer Immune Response.	Chemical Reviews	2019
29548574	Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA.	Bioorganic and Medicinal Chemistry Letters	2018
30121385	Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index.	Nanomedicine: Nanotechnology, Biology, and Medicine	2018
30544798	Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074.	Cells	2018
29876015	Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.	Oncotarget	2018
30464209	Biological activity of Pt prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis.	Scientific Reports	2018
28095394	Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.	British Journal of Cancer	2017
28882160	Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.	Journal of Experimental and Clinical Cancer Research	2017
28837057	The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study.	Toxins	2017
29371972	CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model.	Oncotarget	2017
27036042	Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.	Oncotarget	2016
27367030	Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.	Oncotarget	2016
25749419	Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.	Cancer Letters	2015